Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

Recruiting now · Not applicable

Conditions studied: Atrial Fibrillation (AF), Persistant Atrial Fibrillation, Paroxysmal AF

In brief

To evaluate the safety and effectiveness of the Argá Medtech CSE Ablation System in the treatment of atrial fibrillation.

Key facts

Study ID

NCT06784466

Run by

Arga Medtech SA

People needed

360

Starts

2025-09-10

Expected to finish

2027-08-01

Last updated by the study team

2026-07-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients between the ages of 18 and 80 years, or older than 18 if required by local law.
• Diagnosis of drug refractory, recurrent, paroxysmal or persistent AF:
• a. Symptomatic paroxysmal AF that is less than 7 days in continuous duration, documented by the following: i. Physician documentation of symptomatic recurrent PAF (2 or more episodes) within 6 months prior to enrollment AND ii. At least 1 documented AF episode from any form of rhythm monitoring within 12 months prior to enrollment.
• b. Symptomatic persistent AF that is sustained beyond 7 days and less than 1 year (≥ 7 and ≤ 365 days), documented by the following: i. Physician documentation of at least 1 symptomatic persistent AF episode within 6 months prior to enrollment.
• ii. Either a 24-hour continuous ECG recording documenting continuous AF OR 2 ECGs from any regulatory cleared rhythm monitoring device showing continuous AF taken at least 7 days apart, within 6 months prior to enrollment.
• Effectiveness failure of, intolerance to, or a specific contraindication to at least one Class I or III anti-arrhythmic drug.
• Willing and able to give informed consent.
• Willingness, ability, and commitment to participate in baseline, follow-up, and rhythm monitoring evaluations for the full length of the study.
• Life expectancy >1 year.

You may not qualify if…

• In the opinion of the Investigator, any known contraindication to an AF ablation (including present left atrial [LA] thrombus), trans-esophageal echocardiogram (TEE) or computed tomography (CT) scan, or anticoagulation.
• Any duration of continuous AF lasting longer than 12 months.
• History of any previous left atrial ablation or surgical procedure, including prior left atrial appendage closure.
• AF secondary to electrolyte imbalance, thyroid disease, alcohol, or any other reversible or non-cardiac cause.
• Left ventricular ejection fraction (LVEF) < 35% within 6 months of enrollment (e.g. transthoracic echocardiogram (TTE), multiple-gated acquisition (MUGA), magnetic resonance imaging (MRI), nuclear stress test).
• New York Heart Association (NYHA) Class III or IV.
• Left atrial diameter > 5.0 cm (anteroposterior) within 6 months of enrollment (MRI, CT, TTE, TEE, or physician's note) or non-indexed volume >100mL if left atrial diameter is not available.
• Current or anticipated implant of a permanent pacemaker, implantable cardioverter or resynchronization device, interatrial baffle, foramen ovale occluder, LA appendage closure, or active implantable/insertable cardiac loop recorder/monitor at the time of the ablation procedure.
• Body mass index (BMI) >40.
• Patients who have not been on anticoagulation therapy for at least 3 weeks prior to the Index Procedure.
• Previous cardiac surgery, myocardial infarction, percutaneous coronary intervention or angioplasty (PCI/PTCA) or coronary artery stenting within 3 months prior to enrollment.
• Symptomatic valvular disease, history of cardiac valve surgery, or prosthetic mitral and tricuspid valve(s).
• Presence of pulmonary vein abnormalities of stenosis or stenting.
• Primary pulmonary hypertension.
• Uncontrolled or untreated hypertension (two measurements of >180mmHg systolic or >110 mmHg diastolic at baseline).
• Pre-existing hemi-diaphragmatic paralysis.
• Renal insufficiency with an estimated glomerular filtration rate (eGFR) < 40 mL/min/1.73 m2, or any history of renal dialysis or renal transplant.
• Rheumatic heart disease.
• Unstable angina or ongoing myocardial ischemia.
• Hypertrophic cardiomyopathy, advanced restrictive cardiomyopathy, or severe left ventricular hypertrophy (left ventricular thickness >15mm).
• History of blood clotting or bleeding disease (e.g., thrombocytosis).
• History of documented cerebral infarction, transient ischemic attack, or systemic embolism within 6 months prior to enrollment.
• Active systemic infection.
• Active malignancy or history of treated malignancy within 12 months of enrollment (other than cutaneous basal cell or squamous cell carcinoma, or non-metastatic prostate or breast cancer with life expectancy remaining >1 year).
• Pregnant or lactating (current or anticipated during study follow-up).

Where it is running

• Grandview — Birmingham, Alabama, United States (enrolling)
• Banner University Med Ctr — Phoenix, Arizona, United States (enrolling)
• Arrhythmia Research Group — Jonesboro, Arkansas, United States (enrolling)
• UCSD — San Diego, California, United States (enrolling)
• Ascension / St. Vincent's Jacksonville — Jacksonville, Florida, United States (enrolling)
• Advent Health — Orlando, Florida, United States (enrolling)
• Emory — Atlanta, Georgia, United States (enrolling)
• Northside Hospital — Atlanta, Georgia, United States (enrolling)
• Prairie Education & Research Cooperative — Springfield, Illinois, United States (enrolling)
• Kansas City Heart Rhythm Institute (KCHRI) — Overland Park, Kansas, United States (enrolling)
• Baptist Health Lexington — Lexington, Kentucky, United States (enrolling)
• University of Michigan — Ann Arbor, Michigan, United States (enrolling)
• TriHealth Cincinnati — Cincinnati, Ohio, United States (enrolling)
• Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
• Ohio Health Research and Innovation Institute — Columbus, Ohio, United States (enrolling)
• Trident Medical Center — Charleston, South Carolina, United States (enrolling)
• Texas Cardiac Arrhythmia Research Foundation — Austin, Texas, United States (enrolling)
• Methodist — San Antonio, Texas, United States (enrolling)
• AZorg Aalst — Aalst, Belgium (enrolling)
• Jessa Ziekenhuis — Hasselt, Belgium (enrolling)
• KBC Split — Split, Croatia (enrolling)
• KBC Zagreb — Zagreb, Croatia (enrolling)
• Neuron Medical s.r.o. — Brno, Czech Republic, Czechia (enrolling)
• Institut klinické a experimentální medicíny (IKEM) — Prague, Czech Republic, Czechia (enrolling)
• Motol and Homolka University Hospital — Prague, Czechia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.